TSXV - Delayed Quote CAD

BioSyent Inc. (RX.V)

Compare

11.43

+0.62

(+5.74%)

At close: November 1 at 3:59 p.m. EDT

Key Events

Advanced Chart

Loading Chart for RX.V

9/21 12:03 PM

DELL

Previous Close 10.81
Open 11.45
Bid 11.40 x --
Ask 11.48 x --
Day's Range 11.40 - 11.48
52 Week Range 7.91 - 11.49
Volume 3,127
Avg. Volume 4,403
Market Cap (intraday) 132.445M
Beta (5Y Monthly) 0.93
PE Ratio (TTM) 19.05
EPS (TTM) 0.60
Earnings Date Nov 14, 2024 - Nov 18, 2024
Forward Dividend & Yield 0.18 (1.57%)
Ex-Dividend Date Sep 4, 2024
1y Target Est 11.00

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.

www.biosyent.com

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Drug Manufacturers - Specialty & Generic

Industry

BioSyent Inc.'s (CVE:RX) Stock Is Going Strong: Is the Market Following Fundamentals?

YTD Return

RX.V

25.76%

S&P/TSX Composite index

15.73%

1-Year Return

RX.V

48.40%

S&P/TSX Composite index

28.51%

3-Year Return

RX.V

71.02%

S&P/TSX Composite index

15.30%

5-Year Return

RX.V

98.39%

S&P/TSX Composite index

47.15%

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

RX.V

BioSyent Inc.

11.43

+5.74%

Mkt Cap CAD 132.445M